|
Gene: PPP2R2A |
Gene summary for PPP2R2A |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPP2R2A | Gene ID | 5520 |
Gene name | protein phosphatase 2 regulatory subunit Balpha | |
Gene Alias | B55A | |
Cytomap | 8p21.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | P63151 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5520 | PPP2R2A | CA_HPV_1 | Human | Cervix | CC | 4.24e-02 | 5.10e-02 | 0.0264 |
5520 | PPP2R2A | CCI_1 | Human | Cervix | CC | 2.35e-04 | 9.48e-01 | 0.528 |
5520 | PPP2R2A | CCI_2 | Human | Cervix | CC | 6.88e-14 | 1.20e+00 | 0.5249 |
5520 | PPP2R2A | CCI_3 | Human | Cervix | CC | 5.72e-14 | 8.25e-01 | 0.516 |
5520 | PPP2R2A | sample3 | Human | Cervix | CC | 1.24e-04 | 2.06e-01 | 0.1387 |
5520 | PPP2R2A | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.85e-16 | -5.74e-01 | 0.0155 |
5520 | PPP2R2A | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.12e-05 | -5.47e-01 | -0.1207 |
5520 | PPP2R2A | HTA11_696_2000001011 | Human | Colorectum | AD | 2.44e-06 | -3.63e-01 | -0.1464 |
5520 | PPP2R2A | HTA11_866_3004761011 | Human | Colorectum | AD | 3.61e-05 | -3.67e-01 | 0.096 |
5520 | PPP2R2A | HTA11_10711_2000001011 | Human | Colorectum | AD | 8.89e-05 | -4.99e-01 | 0.0338 |
5520 | PPP2R2A | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.84e-05 | -3.65e-01 | 0.0674 |
5520 | PPP2R2A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.91e-03 | -2.92e-01 | 0.3859 |
5520 | PPP2R2A | A001-C-207 | Human | Colorectum | FAP | 3.98e-03 | -9.24e-02 | 0.1278 |
5520 | PPP2R2A | A015-C-203 | Human | Colorectum | FAP | 2.14e-28 | -4.35e-01 | -0.1294 |
5520 | PPP2R2A | A015-C-204 | Human | Colorectum | FAP | 8.12e-05 | -1.59e-01 | -0.0228 |
5520 | PPP2R2A | A014-C-040 | Human | Colorectum | FAP | 3.81e-04 | -2.59e-01 | -0.1184 |
5520 | PPP2R2A | A002-C-201 | Human | Colorectum | FAP | 7.91e-14 | -1.79e-01 | 0.0324 |
5520 | PPP2R2A | A002-C-203 | Human | Colorectum | FAP | 3.27e-02 | -1.20e-01 | 0.2786 |
5520 | PPP2R2A | A001-C-119 | Human | Colorectum | FAP | 4.70e-05 | -2.77e-01 | -0.1557 |
5520 | PPP2R2A | A001-C-108 | Human | Colorectum | FAP | 1.79e-15 | -2.99e-01 | -0.0272 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
GO:00163114 | Colorectum | CRC | dephosphorylation | 79/2078 | 417/18723 | 1.27e-06 | 7.21e-05 | 79 |
GO:00064705 | Colorectum | CRC | protein dephosphorylation | 57/2078 | 281/18723 | 4.49e-06 | 1.87e-04 | 57 |
GO:00064709 | Endometrium | AEH | protein dephosphorylation | 50/2100 | 281/18723 | 6.41e-04 | 6.23e-03 | 50 |
GO:000647013 | Endometrium | EEC | protein dephosphorylation | 51/2168 | 281/18723 | 7.38e-04 | 7.01e-03 | 51 |
GO:000647017 | Esophagus | HGIN | protein dephosphorylation | 61/2587 | 281/18723 | 1.86e-04 | 3.51e-03 | 61 |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:00702624 | Esophagus | ESCC | peptidyl-serine dephosphorylation | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
GO:00064707 | Lung | IAC | protein dephosphorylation | 60/2061 | 281/18723 | 3.24e-07 | 2.48e-05 | 60 |
GO:00163116 | Lung | IAC | dephosphorylation | 75/2061 | 417/18723 | 1.21e-05 | 3.64e-04 | 75 |
GO:000647012 | Lung | AIS | protein dephosphorylation | 56/1849 | 281/18723 | 2.47e-07 | 2.24e-05 | 56 |
GO:001631112 | Lung | AIS | dephosphorylation | 69/1849 | 417/18723 | 1.27e-05 | 4.78e-04 | 69 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0407113 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa04530 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa04152 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa04071 | Colorectum | AD | Sphingolipid signaling pathway | 43/2092 | 121/8465 | 4.83e-03 | 2.28e-02 | 1.45e-02 | 43 |
hsa04728 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
hsa03015 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa045301 | Colorectum | AD | Tight junction | 76/2092 | 169/8465 | 5.49e-09 | 9.69e-08 | 6.18e-08 | 76 |
hsa041521 | Colorectum | AD | AMPK signaling pathway | 47/2092 | 121/8465 | 3.74e-04 | 2.82e-03 | 1.80e-03 | 47 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa040711 | Colorectum | AD | Sphingolipid signaling pathway | 43/2092 | 121/8465 | 4.83e-03 | 2.28e-02 | 1.45e-02 | 43 |
hsa047281 | Colorectum | AD | Dopaminergic synapse | 46/2092 | 132/8465 | 5.55e-03 | 2.48e-02 | 1.58e-02 | 46 |
hsa030151 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP2R2A | SNV | Missense_Mutation | novel | c.1042N>A | p.Glu348Lys | p.E348K | P63151 | protein_coding | deleterious(0.02) | probably_damaging(0.951) | TCGA-44-2662-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Other, specify in notesGSK Mage Vaccine Study | rec | PD |
PPP2R2A | SNV | Missense_Mutation | novel | c.798N>A | p.Met266Ile | p.M266I | P63151 | protein_coding | deleterious(0.01) | benign(0.232) | TCGA-44-2668-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PPP2R2A | SNV | Missense_Mutation | c.1247N>T | p.Asp416Val | p.D416V | P63151 | protein_coding | deleterious(0.04) | benign(0.367) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PPP2R2A | SNV | Missense_Mutation | c.532N>T | p.Pro178Ser | p.P178S | P63151 | protein_coding | deleterious(0.04) | benign(0.085) | TCGA-18-3421-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PPP2R2A | SNV | Missense_Mutation | rs759228133 | c.626N>A | p.Arg209Gln | p.R209Q | P63151 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-58-8391-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
PPP2R2A | SNV | Missense_Mutation | c.1138N>C | p.Asp380His | p.D380H | P63151 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-NC-A5HN-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PPP2R2A | insertion | Frame_Shift_Ins | novel | c.502dupA | p.Arg168LysfsTer8 | p.R168Kfs*8 | P63151 | protein_coding | TCGA-69-7974-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
PPP2R2A | SNV | Missense_Mutation | novel | c.798N>A | p.Met266Ile | p.M266I | P63151 | protein_coding | deleterious(0.01) | benign(0.232) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PPP2R2A | SNV | Missense_Mutation | novel | c.1144N>G | p.Asn382Asp | p.N382D | P63151 | protein_coding | tolerated(0.42) | benign(0) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PPP2R2A | SNV | Missense_Mutation | c.706A>C | p.Thr236Pro | p.T236P | P63151 | protein_coding | deleterious(0) | possibly_damaging(0.773) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |